In 2019, the Company sublicensed its technologies to Animal Life Sciences, Inc. (ALI), to enable research and commercialization for non-human use and share development data.
The expenses recognized under the agreements were $ 212,000 and $ 211,000 for the three months ended March 31, 2026 and 2025 , respectively . The Company entered into a research agreement with MD And…
Moleculin Biotech, Inc. Customers
No clients on recordNo downstream customers found in our database for Moleculin Biotech, Inc..
Moleculin Biotech, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
MBRX-DEBT-10882
Warrants outstanding: 107802
90%
xbrl warrant detail from xbrl 2025-12-31.
MBRX-DEBT-10883
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
MBRX-DEBT
Debt stack $185,000
90%
Market cache reports total debt of $185,000.
Moleculin Biotech, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Moleculin Biotech, Inc..
Moleculin Biotech, Inc. Ownership
Holder
Name
Confidence
Evidence
MBRX-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 3 tracked holders.
Moleculin Biotech, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
